<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>研发客研究院 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-25T13:30:18+08:00</updated>
  <subtitle>独立报告、专业分析、深度解读</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>只有一个候选产品却能顺利融资的Olema｜公司</title>
    <updated>2020-12-24T12:34:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-24:/s/asOaCzChbUtiYNnzqVF7ew</id>
    <link href="https://mp.weixin.qq.com/s/asOaCzChbUtiYNnzqVF7ew" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>PSR filing system landed</title>
    <updated>2020-12-22T16:01:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-22:/s/va4MSsZ6i7aLSuL2lK2Pdg</id>
    <link href="https://mp.weixin.qq.com/s/va4MSsZ6i7aLSuL2lK2Pdg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>What’s new for drug R&amp;D and evaluation communication in China</title>
    <updated>2020-12-21T14:06:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-21:/s/rZSph4jcHodxUsP1OJb1_Q</id>
    <link href="https://mp.weixin.qq.com/s/rZSph4jcHodxUsP1OJb1_Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>“惠民保”迎来首份监管文件｜观点</title>
    <updated>2020-12-21T11:06:54+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-21:/s/fmDFTvMZpoB8AHd9PRdgTQ</id>
    <link href="https://mp.weixin.qq.com/s/fmDFTvMZpoB8AHd9PRdgTQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>PharmaMar：向海洋索药｜公司</title>
    <updated>2020-12-18T09:15:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-18:/s/COgg9kR9I87t11UIrE58xg</id>
    <link href="https://mp.weixin.qq.com/s/COgg9kR9I87t11UIrE58xg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>First Regulation for Customized Commercial Insurance BPI</title>
    <updated>2020-12-13T12:17:03+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-13:/s/X4B5JSRL4jF98wUU8t0dCg</id>
    <link href="https://mp.weixin.qq.com/s/X4B5JSRL4jF98wUU8t0dCg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Kinaset引进JAK抑制剂吸入粉剂，专攻严重哮喘，并获A轮融资 | 公司</title>
    <updated>2020-12-11T11:51:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/v2llUXA9g04Mvr8z97Zbyg</id>
    <link href="https://mp.weixin.qq.com/s/v2llUXA9g04Mvr8z97Zbyg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Vedanta Biosciences：活菌疗法并非都得“吃粪便” | 公司</title>
    <updated>2020-12-04T09:51:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/ysCJFDj7GSjAeCYWAny00w</id>
    <link href="https://mp.weixin.qq.com/s/ysCJFDj7GSjAeCYWAny00w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>凯信远达：专注血液肿瘤，期待扭亏为盈｜公司</title>
    <updated>2020-11-27T10:02:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-27:/s/dCveSKY6M-DsxgYpGJZxCg</id>
    <link href="https://mp.weixin.qq.com/s/dCveSKY6M-DsxgYpGJZxCg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>NK细胞是肿瘤免疫下一个风口？被赛诺菲收购的Kiadis是什么来头？ | 公司分析</title>
    <updated>2020-11-20T02:50:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/4-iCYw43bmtqDtz5z2-sVA</id>
    <link href="https://mp.weixin.qq.com/s/4-iCYw43bmtqDtz5z2-sVA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>